<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632446</url>
  </required_header>
  <id_info>
    <org_study_id>IMIB-2020-UPCS</org_study_id>
    <nct_id>NCT04632446</nct_id>
  </id_info>
  <brief_title>Upgrade Program Implementation at Colorrectal Surgery and Complications: Early Diagnosis</brief_title>
  <official_title>Upgrade Program Implementation at Colorrectal Surgery and Complications: Early Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anastomotic leak (AL) is a very serious complication in colorectal surgery not only&#xD;
      because of its severity but its frequency. Other facet for study, besides the risk factor and&#xD;
      prevention, is the AL early diagnostic, due to minimize the clinical consequences and&#xD;
      severity; and avoid the failure-to-recue. Several studies analyze the Creactive protein (CRP)&#xD;
      and Procalcitonine (PCT) usefulness in AL predictor before the clinical signs appear.&#xD;
&#xD;
      At a prospective observational study carry on our center, it concluded that CRP at 3rd day&#xD;
      after surgery over 15mg/dl was a very important AL predictor, even before the clinical&#xD;
      changes appear. The aim of this study is minimize the severity complications and the&#xD;
      mortality due to AL appears. The aim of this study is minimize the severity complications and&#xD;
      the mortality due to AL by means of introduces an upgrade program in which a CT scan will be&#xD;
      conduct in all the patients with high CRP levels at 3rd, 4th or 5th postoperative day, with&#xD;
      the goal to know the AL early and make all the therapeutic step to minimize the consequences.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of morbidity</measure>
    <time_frame>1 year</time_frame>
    <description>Number of reoperations, readmissions for infections associated or other medical complications, terminal stomata</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Number of related exits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Compare hospital stay and ICU stay of patients undergoing elective colorectal surgery before and after the improvement program.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Evaluate the difference in the incidence of anastomosis leak after the implementation of the improvement program</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Surgery</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early diagnosis</intervention_name>
    <description>Early diagnosis. Upgrade program implementation.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who underwent elective colorectal surgery consecutively will be included, in&#xD;
        which an anastomosis have been performed (neoplastic and non-neoplastic pathology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years of age.&#xD;
&#xD;
          -  Patients undergoing elective colorectal surgery due to neoplastic or non-neoplastic&#xD;
             etiology.&#xD;
&#xD;
          -  Patients with an anastomosis performed in the surgical act.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who require transfer to another center.&#xD;
&#xD;
          -  Patients with fatal evolution: those who require urgent reoperation for an inarverted&#xD;
             perforation, early leakage of anastomosis or death before the third postoperative day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graciela Valero-Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>- Hospital Morales Meseguer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Graciela Valero-Navarro, MD</last_name>
    <phone>968360900</phone>
    <email>valerograciela@um.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>- Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graciela Valero-Navarro, MD</last_name>
      <phone>968360900</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

